Table 1.
Percentage of CD3+CD4+IFNγ+ and CD3+CD8+IFNγ+ cells in the spleens from mice vaccinated with the PLGA-based NPs and challenged with Leishmania infantum
| IFNγ production from CD4+ or CD8+ T cells
|
||||||||
|---|---|---|---|---|---|---|---|---|
| PBS | sLiAg + MPLA | PLGA | PLGA-sLiAg | PLGA-sLiAg-MPLA | p8-PLGA | p8-PLGA-sLiAg | p8-PLGA-sLiAg-MPLA | |
| CD3+CD4+IFNγ+ | ||||||||
| Pre-challenge | 1.54±0.50 | 1.35±0.88 | 1.28±0.35 | 1.03±0.20 | 0.85±0.46 | 2.15±0.43 | 2.04±1.26 | 0.55±0.11 |
| 2 months pc | 0.89±0.34 | 0.76±0.14 | 0.54±0.16 | 0.99±0.02 | 0.98±0.10 | 1.16±0.16 | 1.22±0.37 | 1.11±0.24 |
| 4 months pc | 1.96±0.63 | 1.46±0.16 | 2.29±0.06 | 3.19±0.48* | 2.79±0.39* | 2.14±0.49 | 2.99±0.50* | 0.71±0.31 |
| CD3+CD8+IFNγ+ | ||||||||
| Pre-challenge | 1.25±0.31 | 2.14±0.40 | 2.69±0.23 | 2.67±0.37 | 2.61±0.63 | 2.63±0.70 | 5.43±0.09*** | 4.92±1.60*** |
| 2 months pc | 2.49±0.96 | 1.39±0.24 | 2.30±0.50 | 4.06±0.68 | 3.98±0.19 | 4.35±0.79 | 6.97±0.87*** | 6.01±1.06** |
| 4 months pc | 8.91±1.05 | 4.39±0.04 | 7.27±2.57 | 5.46±3.94 | 9.40±3.25 | 5.13±0.22 | 13.30±2.54* | 12.22±2.87* |
Note: The values represent the mean ± standard deviation. Statistical significance at the level of
*
P<0.05,
**
P<0.01 and
***
P<0.001 compared to PBS control group.
Abbreviations: PLGA, poly(D,L-lactide-co-glycolide); NPs, nanoparticles; PBS, phosphate-buffered saline; sLiAg, soluble Leishmania infantum antigens; MPLA, monophosphoryl lipid A; p8, eight-amino-acid peptide; pc, post-challenge.